Vascular Disruptive Agents for the Treatment of Cancer
Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. T
- PDF / 6,968,624 Bytes
- 258 Pages / 439.37 x 666.142 pts Page_size
- 37 Downloads / 172 Views
w
Tim Meyer Editor
Vascular Disruptive Agents for the Treatment of Cancer
Editor Tim Meyer Senior Lecturer in Medical Oncology UCL Cancer Institute Paul O’Gorman Building University College London 72 Huntley Street London WC1E 6BT [email protected]
ISBN 978-1-4419-6608-7 e-ISBN 978-1-4419-6609-4 DOI 10.1007/978-1-4419-6609-4 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010934905 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Contents
Development of Vascular Disrupting Agents.................................................. Graeme J. Dougherty and David J. Chaplin
1
Part I Pre-Clinical Development The Discovery and Characterisation of Tumour Endothelial Markers......................................................................................... 31 Dario Neri and Roy Bicknell The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs)............................................. 49 R. Barbara Pedley and Gillian M. Tozer Combination Therapy with Chemotherapy and VDAs................................. 77 Givlia Taraboletti, Katiuscia Bonezzi, and Raffaella Giavazzi Lessons from Animal Imaging in Preclinical Models.................................... 95 Lesley D. McPhail and Simon P. Robinson Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action................................................. 117 Yuval Shaked, Paul Nathan, Laura G.M. Daenen, and Robert S. Kerbel Part II Imaging in the Development of Vascular Disruptive Agents MRI to Assess Vascular Disruptive Agents..................................................... 137 Martin Zweifel and Anwar R. Padhani Contrast Ultrasound in Imaging Tumor Angiogenesis.................................. 165 Grzegorz Korpanty and Rolf A. Brekken
v
vi
Contents
Part III Clinical Development The Clinical Development of Tubulin Binding Vascular Disrupting Agents............................................................................................ 183 Martin Zweifel and Gordon Rustin ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy........................................................................................... 217 Br
Data Loading...
